FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (3:1) w/o Sodium Bicarbonate, Calcium Chloride: 1X Liquid

FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham’s F-12 Nutrient Mixture (DMEM/F-12) (3:1) w/o Sodium Bicarbonate, Calcium Chloride: 1X Liquid

Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid DMEM/F-12 (3:1) engineered for microfluidic channels, organ-on-a-chip (OoC), and microphysiological systems (MPS). Formulated without sodium bicarbonate or calcium chloride for custom buffering and calcium titration. Manufactured under ISO 13485:2016 in an ISO Class 5 fill environment using Ultrapure Type 1 water (18.2 MΩ·cm).

• Bicarbonate-free, calcium chloride-free DMEM/F-12 (3:1) with glucose (3.8255 g/L), L-glutamine (474.5 mg/L) and sodium pyruvate (27.525 mg/L) retained
• Quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final cutoff, beyond standard single-stage 0.22 µm filtration
• Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85> Bacterial Endotoxins Test), controlled per manufacturing batch
• Manufactured under an ISO 13485:2016 quality management system; final QC and packaging at Diagnocine, Totowa, NJ
• Bicarbonate-free design permits CO₂-independent incubation with custom HEPES or bicarbonate buffering matched to your application
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm) for trace-metal and organic-carbon control
• 4× BME amino acid and vitamin concentrations for extended microphysiological system (MPS) perfusion
• Custom pH, glucose, HEPES, salts and nutrient adjustments available on request — support@diagnocine.com

Engineered where standard media fails

Conventional 0.22 µm filtered media allows mycoplasma (0.2–0.3 µm), sub-visible particulates, and microaggregates to pass freely — clogging microchannels, corrupting biosensors, and invalidating metabolic assays. FluxMPS™ closes that gap.

Quadruple-stage filtration system

FluxMPS™ DCP-DMF12-BCT1X undergoes a validated four-stage sequential filtration reaching a final pore size of 0.04 µm, beyond the single-stage 0.22 µm filtration used in conventional cell culture media.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris, and protein aggregates. Protects the first 0.04 µm final-filter cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass. Retains sub-micron particulates and microaggregates, including mycoplasma (0.2–0.3 µm), that pass a conventional 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm final-filter cartridge for full-redundancy sterile processing.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill in a validated ISO Class 5 (Class 100) laminar-flow workstation.

Optimized for next-generation cell biology platforms

FluxMPS™ DCP-DMF12-BCT1X is validated for applications where microchannel cleanliness, signal fidelity, and metabolic precision are critical.

Automated Bioreactors & Robotics

For automated perfusion bioreactors and robotic liquid-handling platforms, Diagnocine offers an optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant of this formulation, adding 0.02 µm and 0.01 µm stages beyond the standard 0.04 µm polish.

• Total Particulate Exclusion — sub-10 nm cut-off for zero-tolerance valve and sensor lines
• Valve & Sensor Protection — minimizes microvalve fouling and optical-sensor drift over long runs
• Extended Perfusion Stability — reduced servicing frequency for continuous, unattended bioreactor operation

Inquiry Required: the 0.01 µm MPS Grade variant is produced to order. Contact support@diagnocine.com to request a quote.

Full technical specification

Every lot of FluxMPS™ DCP-DMF12-BCT1X is released against comprehensive multi-parameter QC specifications.

Full composition (mg/L)

Total: 49 components (10 inorganic salts, 21 amino acids, 9 vitamins, 9 other components) organized into 3 navigation tabs. All values are per-lot verified and reported on the Certificate of Analysis (CoA).

Manufacturing & compliance

Every batch subjected to multi-parameter lot-release testing before distribution.

How DCP-DMF12-BCT1X compares

Critical advantages in filtration, mycoplasma barrier, water quality, and QC depth for MPS and microfluidic applications.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-DMF12-BCT1X.

Supporting literature

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Vander Heiden MG, et al. Understanding the Warburg effect. Science. 2009;324:1029–1033. doi:10.1126/science.1160809
4. Sontheimer-Phelps A, et al. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer. 2019;19:65–81. doi:10.1038/s41568-018-0104-6
5. van Duinen V, et al. Microfluidic 3D cell culture. Curr Opin Biotechnol. 2015;35:118–126. doi:10.1016/j.copbio.2015.05.002
6. Jang KJ, et al. Reproducing human drug toxicities using a Liver-Chip. Sci Transl Med. 2019;11:eaax5516. doi:10.1126/scitranslmed.aax5516
7. Kasendra M, et al. Primary human Small Intestine-on-a-Chip. Sci Rep. 2018;8:2871. doi:10.1038/s41598-018-21201-7
8. Skardal A, et al. Multi-tissue organ-on-a-chip platform. Sci Rep. 2017;7:8837. doi:10.1038/s41598-017-08879-x